The development of osimertinib resistance in EGFR L858R, T790M NSCLC and xenografts was related to secondary mutations in BRAF and PIK3C2A combined with reduced EGFR-T790M mutations. The gene discussed is PIK3C2A; the disease is non-small cell lung carcinoma.